Clinical Trials

Numerous clinical trials spanning Phase I through Phase IV evaluate risperidone across various psychiatric and neurological conditions, including schizophrenia, schizoaffective disorder, bipolar I disorder, treatment-resistant depression, and post-operative confusion. Sponsored by academic medical centers, university hospitals, and industry partners, these studies comprise completed, currently recruiting, terminated, and withdrawn recruitment statuses. Furthermore, several clinical trials focus on novel extended-release and subcutaneous formulations designed for schizophrenia symptom management and relapse prevention.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT07152184 NOT_YET_RECRUITING
Patient With Schizophrenia Spectrum Disorder; NLM Classification WM 203, Psychology:Schizophrenic Psychology; Schizophrenia Spectrum and Other Psychotic Disorders
University Hospital, Strasbourg, France
 2026-10-01 PHASE2
NCT06969755 RECRUITING
Schizophenia Disorder
Northwell Health
 2024-09-04 PHASE4
NCT07483294 RECRUITING
Psychosis; Acute
Northwell Health
 2025-11-01 PHASE4
NCT07665073 NOT_YET_RECRUITING
Bipolar 1 Disorder
Pakistan Institute of Medical Sciences
 2027-06 PHASE4
NCT07490353 RECRUITING
Depression - Major Depressive Disorder; Anhedonia
Medical University of Vienna
 2025-11-01 PHASE1
NCT07047651 ACTIVE_NOT_RECRUITING
Treatment Resistant Schizophrenia; Treatment Resistant Bipolar Disorder
Dr. Stavroula Rakitzi
 2025-06-04 PHASE4
NCT06768944 RECRUITING
Investigating the Importance of the Subjective Psychedelic Experience
University of Calgary
 2026-05-15 PHASE2
NCT07565428 RECRUITING
Negative Symptoms of Schizophrenia
Minerva Neurosciences
 2026-04-23 PHASE3
NCT04478838 RECRUITING
Schizophrenia and Related Disorders; Drug Administration Schedule; Drug Therapy; Antipsychotic Agents
Centre for Addiction and Mental Health
 2022-06-06 PHASE4
NCT00768820 RECRUITING
Velocardiofacial Syndrome; Williams Syndrome; Fragile X Syndrome
The Chaim Sheba Medical Center
 2001-05 PHASE4
NCT07503002 NOT_YET_RECRUITING
Major Depression Moderate; Major Depression Severe; Major Depression
Johns Hopkins University
 2026-08-31 PHASE1
NCT04580134 RECRUITING
Schizophrenia; Schizoaffective Disorder; Bipolar 1 Disorder
University of Texas Southwestern Medical Center
 2022-03-01 PHASE4
NCT06512220 RECRUITING
Treatment Resistant Depression
Centre for Addiction and Mental Health
 2025-04-21 PHASE2
NCT06878833 WITHDRAWN
Schizophrenia; Schizoaffective Disorder
Lyndra Inc.
 2025-04-18 PHASE3
NCT05401019 WITHDRAWN
Obsessive-Compulsive Disorder
Clinical Academic Center (2CA-Braga)
 2022-06 PHASE2
NCT06482554 RECRUITING
Apathy; Schizophrenia; Schizophrenia; Psychosis
Louisiana State University Health Sciences Center Shreveport
 2024-06 PHASE3
NCT05710237 COMPLETED
Treatment-resistant Depression
Centre for Addiction and Mental Health
 2023-07-01 PHASE2
NCT07524868 COMPLETED
Schizophrenia Patients; Auditory Hallucination
Hasanuddin University
 2025-11-01
NCT07609953 COMPLETED
Schizophrenia
Hasanuddin University
 2025-11-01
NCT07523256 COMPLETED
Schizophrenia; Psychotic Disorders
Rinvil Renaldi
 2025-11-01
NCT07541157 COMPLETED
Schizophrenia Patients
Hasanuddin University
 2025-09-01
NCT07575516 COMPLETED
Schizophrenia Patients; Neuroinflammation
Hasanuddin University
 2025-10-01 PHASE2
NCT06581302 RECRUITING
Psychotic Disorders
Shanghai Jiao Tong University School of Medicine
 2024-09-01
NCT06368726 ENROLLING_BY_INVITATION
Attention; Visual Perceptual Weakness; Social Behavior; Fluency Disorder; EEG With Periodic Abnormalities
Spanish Foundation for Neurometrics Development
 2024-04-01 PHASE1
NCT04903353 COMPLETED
Weight Gain; Autism Spectrum Disorder; Medication Side Effect
Vanderbilt University Medical Center
 2022-02-01 PHASE4
NCT04105231 ACTIVE_NOT_RECRUITING
Dual Diagnosis
Lone Baandrup
 2021-06-01 PHASE2
NCT06236451 COMPLETED
Schizophrenia
All India Institute of Medical Sciences, Bhubaneswar
 2024-04-05 PHASE4
NCT07060872 NOT_YET_RECRUITING
Age 3 to 7 Years; Mild Autism Spectrum; no Other Illness or Disorder
Shahid Sadoughi University of Medical Sciences and Health Services
 2025-07-07
NCT06276361 COMPLETED
Schizophrenia
Rovi Pharmaceuticals Laboratories
 2023-09-26 PHASE1
NCT07671040 COMPLETED
Schizophrenia; Cognitive and Executive Dysfunction; Neuroinflammation
Hasanuddin University
 2025-03-01
NCT06060886 UNKNOWN
Schizophrenia; Treatment-resistant Schizophrenia; Side Effect; Lipid Metabolism Disorders; Diabetes; NAFLD; Psychosis
Consorcio Centro de Investigación Biomédica en Red (CIBER)
 2023-11-01 PHASE4
NCT07477301 COMPLETED
Schizophrenia; Cognitive Dysfunction; Inflamation
Hasanuddin University
 2024-12-01 PHASE2
NCT04529226 UNKNOWN
Psychosis; Intellectual Disability
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
 2020-11-26 PHASE2
NCT04071639 UNKNOWN
Huntington Disease
Second Affiliated Hospital, Zhejiang University, School of Medicine
 2020-03-12 PHASE1
NCT07116850 COMPLETED
Schizophrenia Disorder
The First Hospital of Hebei Medical University
 2024-01-01
NCT04624243 COMPLETED
Schizophrenia
Merck Sharp & Dohme LLC
 2020-12-15 PHASE2
NCT05868720 UNKNOWN
The Goal of This Trial is to to Compare the Effect of Risperidone vs Aripiprazole in Terms of Change in Serum Glutathione Level
All India Institute of Medical Sciences, Bhubaneswar
 2023-07-01
NCT05146245 UNKNOWN
Autism Spectrum Disorder
Erasmus Medical Center
 2021-12-01 PHASE4
NCT04940039 COMPLETED
Schizophrenia
Janssen-Cilag International NV
 2021-07-22 PHASE4
NCT06218979 COMPLETED
Psychosis; Food-drug Interaction
Helsinki University Central Hospital
 2023-12-08 PHASE1
NCT05890768 WITHDRAWN
Psychosis
University of New Mexico
 2023-05-11 PHASE4
NCT05542264 COMPLETED
Schizophrenia
Otsuka Pharmaceutical Development & Commercialization, Inc.
 2022-11-15 PHASE1
NCT04201834 COMPLETED
Huntington Disease; Chorea
University of Rochester
 2020-08-13 PHASE2
NCT06218979 Recruiting
Psychosis|Food-drug Interaction
Helsinki University Central Hospital|University of Helsinki
 2023-12-04 Phase 1
NCT05779241 COMPLETED
Schizophrenia; Schizoaffective Disorder
Lyndra Inc.
 2023-04-13 PHASE3
NCT05402111 COMPLETED
Schizophrenia
Otsuka Pharmaceutical Development & Commercialization, Inc.
 2022-06-13 PHASE1
NCT03510325 COMPLETED
Schizophrenia
Shanghai Mental Health Center
 2019-02-12 PHASE3
NCT05710237 Recruiting
Treatment-resistant Depression
Centre for Addiction and Mental Health
 2023-07-01 Phase 2
NCT03323437 COMPLETED
Schizophrenia Spectrum and Other Psychotic Disorders
Weill Medical College of Cornell University
 2017-09-15 PHASE4
NCT04418466 COMPLETED
Schizophrenia
Delpor, Inc.
 2021-04-01 PHASE1; PHASE2
NCT04446234 UNKNOWN
Schizophrenia
Shanghai Mental Health Center
 2021-05 PHASE4
NCT04512066 COMPLETED
Schizophrenia, Schizoaffective Disorder
Hoffmann-La Roche
 2020-09-08 PHASE2
NCT05374356 Unknown status
Post-Operative Confusion
University of Manitoba
 2022-05 Not Applicable
NCT05491720 COMPLETED
Autism Spectrum Disorder
The National Brain Mapping Laboratory (NBML)
 2020-08-15 PHASE1
NCT03893825 COMPLETED
Schizophrenia
Teva Branded Pharmaceutical Products R&D, Inc.
 2019-04-17 PHASE3
NCT01451736 COMPLETED
Schizophrenia (Recent-onset)
University of California, Los Angeles
 2011-10 PHASE4
NCT05179525 COMPLETED
Schizophrenia
Rovi Pharmaceuticals Laboratories
 2021-03-09 PHASE1
NCT03227562 TERMINATED
Anxiety State
Marion Trousselard
 2017-09-01 PHASE3
NCT06200584 COMPLETED
Antipsychotics and Neuroleptics Toxicity
Dr Rabia Arshad
 2021-01-01
NCT04639960 TERMINATED
22q11.2 Deletion Syndrome
University of Geneva, Switzerland
 2017-09-29
NCT03837860 TERMINATED
Opioid Abuse, Unspecified; Opioid Dependence
The University of Texas Health Science Center at San Antonio
 2019-04-01 EARLY_PHASE1
NCT04567524 COMPLETED
Schizophrenia Schizoaffective
Lyndra Inc.
 2020-08-13 PHASE2
NCT03883204 UNKNOWN
Schizophrenia; Psychotic Disorders; Psychosis
Fundación Marques de Valdecilla
 2015-01-01 PHASE4
NCT00825045 UNKNOWN
Schizophrenia; Schizoaffective Disorder; Schizophreniform Disorder
Centre for Addiction and Mental Health
 2008-12
NCT03503318 COMPLETED
Schizophrenia
Teva Branded Pharmaceutical Products R&D, Inc.
 2018-04-27 PHASE3
NCT04567524 Completed
Schizophrenia Schizoaffective
Lyndra Inc.|Worldwide Clinical Trials
 2020-08-13 Phase 2
NCT03790085 UNKNOWN
Schizophrenia; Major Depressive Disorder; Anxiety Disorders
Tianjin Medical University General Hospital
 2018-09-01 EARLY_PHASE1
NCT03978832 COMPLETED
Schizophrenia
Indivior Inc.
 2019-06-28 PHASE4
NCT03870880 COMPLETED
Schizophrenia
Rovi Pharmaceuticals Laboratories
 2017-08-25 PHASE3
NCT03148509 UNKNOWN
Diagnosis and Treatment of Depression
Peking University
 2017-06-01 PHASE4
NCT03713658 COMPLETED
Schizophrenia
Janssen Research & Development, LLC
 2018-10-18 PHASE4
NCT02431702 COMPLETED
Schizophrenia; Psychotic Disorders
Janssen Scientific Affairs, LLC
 2015-07-08 PHASE3
NCT03557931 COMPLETED
Schizophrenia
Astellas Pharma Global Development, Inc.
 2018-07-13 PHASE2
NCT02926976 UNKNOWN
Schizophrenia
Shanghai Mental Health Center
 2016-11
NCT04587115 COMPLETED
Addiction
The University of Texas Health Science Center at San Antonio
 2017-06-16 EARLY_PHASE1
NCT03978832 Completed
Schizophrenia
Indivior Inc.
 2019-06-28 Phase 4
NCT03090503 UNKNOWN
Schizophrenia; Psychotic Disorders; Psychosis
Fundación Marques de Valdecilla
 2014-06 PHASE4
NCT02562287 UNKNOWN
Bipolar Disorder
Hospital de Clinicas de Porto Alegre
 2015-10 PHASE4
NCT03568500 COMPLETED
Schizophrenia; Schizoaffective Disorder; First Episode Psychosis
Otsuka Pharmaceutical Development & Commercialization, Inc.
 2018-05-21 PHASE4
NCT03527186 COMPLETED
Schizophrenia
Rovi Pharmaceuticals Laboratories
 2018-07-09 PHASE1
NCT03230864 TERMINATED
Treatment-resistant Schizophrenia
H. Lundbeck A/S
 2017-07-20 PHASE3
NCT03160521 COMPLETED
Acute Schizophrenia
Rovi Pharmaceuticals Laboratories
 2017-06-02 PHASE3
NCT04076371 COMPLETED
Schizophrenia
Beijing HuiLongGuan Hospital
 2012-01
NCT02717195 COMPLETED
Schizophrenia
H. Lundbeck A/S
 2016-04 PHASE3
NCT01878513 COMPLETED
Schizophrenia; Schizoaffective Disorder; Psychotic Disorder Not Otherwise Specified; Severe Bipolar Disorder With Psychotic Features
Northwell Health
 2009-09-23
NCT03075657 COMPLETED
Schizophrenia
All India Institute of Medical Sciences, Bhubaneswar
 2017-05-01 PHASE4
NCT02532491 UNKNOWN
Schizophrenia; Psychotic Disorders
Fundación Marques de Valdecilla
 2014-05 PHASE4
NCT02063945 TERMINATED
Attention Deficit/Hyperactivity Disorder; Oppositional Defiant Disorder; Conduct Disorder
Sheba Medical Center
 2017-02-01 PHASE4
NCT03055338 COMPLETED
Schizophrenia, Acute Episode
Merck Sharp & Dohme LLC
 2017-03-08 PHASE2
NCT03220867 WITHDRAWN
Healthy
Xian-Janssen Pharmaceutical Ltd.
 2017-12-11 PHASE1
NCT03887754 COMPLETED
Autism Spectrum Disorder
Minia University
 2016-01 PHASE2
NCT02282085 UNKNOWN
Schizophrenia
Matt Byerly
 2014-12 PHASE4
NCT02773576 COMPLETED
Schizophrenia
Braeburn Pharmaceuticals
 2016-04 PHASE3
NCT02051387 COMPLETED
Schizophrenia
Central Institute of Mental Health, Mannheim
 2013-01 PHASE1
NCT02658357 COMPLETED
Schizophrenia; Schizo-affective Disorder
Braeburn Pharmaceuticals
 2015-10 PHASE2
NCT02634320 COMPLETED
Schizophrenia
Alkermes, Inc.
 2015-12 PHASE4
NCT02374567 TERMINATED
Dementia; Depression; Schizophrenia; Psychosomatic Disorders; Anxiety Disorders
Hannover Medical School
 2015-01 PHASE3
NCT01639872 COMPLETED
Schizophrenia; Cannabis Abuse; Cannabis Dependence; Dual Diagnosis
Dartmouth-Hitchcock Medical Center
 2013-05-01 PHASE4
NCT01913327 TERMINATED
Schizophrenia; Schizoaffective Disorder; Schizophreniform Disorder
University of California, San Francisco
 2013-04 PHASE4
NCT03019887 COMPLETED
Schizophrenia Relapse
Juntendo University
 2011-04
NCT02661347 WITHDRAWN
Schizophrenia; Schizophreniform; Schizoaffective Disorder; Psychosis Not Otherwise Specified (NOS)
Northwell Health
 2016-02
NCT02650102 UNKNOWN
Schizophrenia
Shanxi Medical University
 2013-01 PHASE1; PHASE2
NCT02634463 COMPLETED
Immunoassay; Antipsychotic
Janssen Research & Development, LLC
 2015-11-09 PHASE1
NCT01626872 COMPLETED
Schizophrenia
Tanabe Pharma Corporation
 2012-09 PHASE2; PHASE3
NCT01171937 COMPLETED
Autism
University of California, Los Angeles
 2008-09 PHASE2
NCT02538081 WITHDRAWN
Schizophrenia
VA Office of Research and Development
 2015-08 PHASE1; PHASE2
NCT02469155 COMPLETED
Schizophrenia
Intra-Cellular Therapies, Inc.
 2015-06 PHASE3
NCT01931059 COMPLETED
Imaging of the Brain and Antipsychotics; Neuronal Network Changes
Northwell Health
 2013-07
NCT02307396 COMPLETED
Schizophrenia; Schizophrenia and Disorders With Psychotic Features; Schizoaffective Disorders
Technical University of Munich
 2015-02-01 PHASE4
NCT02758067 WITHDRAWN
Schizophrenia
H. Lundbeck A/S
 2016-06 PHASE3
NCT02118688 WITHDRAWN
Delirium; Agitation
Rochester General Hospital
 2011-03 PHASE4
NCT02462473 TERMINATED
Schizophrenia; Schizoaffective Disorder
Janssen Research & Development, LLC
 2015-05 PHASE2
NCT02411526 COMPLETED
Schizophrenia; Schizoaffective Disorder
Zogenix, Inc.
 2015-02 PHASE1
NCT01786239 COMPLETED
Schizophrenia; Schizophreniform Disorder; Schizoaffective Disorder; Bipolar Disorder; Psychosis NOS
Delbert Robinson
 2013-05
NCT00716755 COMPLETED
Schizophrenia; Schizoaffective Disorder; Schizophreniform Disorder; Delusional Disorder; Psychotic Disorder
Centre for Addiction and Mental Health
 2009-10
NCT01333072 COMPLETED
Autistic Disorder
Medical University of South Carolina
 2011-07 PHASE4
NCT01625000 COMPLETED
Schizophrenia
Tanabe Pharma Corporation
 2012-05 PHASE2; PHASE3
NCT02593734 COMPLETED
Schizophrenia; Mood Disorders,; Anxiety Disorder
University of Ghana Medical School
 2013-07 PHASE4
NCT02573701 COMPLETED
Schizophrenia
Hospital Psiquiatrico Infantil Dr. Juan N. Navarro, Mexico
 2011-10
NCT01670071 TERMINATED
Schizophrenia
Johnson & Johnson Taiwan Ltd
 2013-01 PHASE4
NCT02453893 UNKNOWN
Schizophrenia
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
 2013-11 PHASE3
NCT02002832 COMPLETED
Schizophrenia
Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
 2013-12 PHASE3
NCT01625897 COMPLETED
Schizophrenia
Tanabe Pharma Corporation
 2012-05 PHASE2; PHASE3
NCT02086786 COMPLETED
Schizophrenia
Rovi Pharmaceuticals Laboratories
 2014-03 PHASE2
NCT02137616 UNKNOWN
Psychotic Disorders
Central South University
 2012-06
NCT02040883 UNKNOWN
Schizophrenia
Qingyun Yin
 2014-02 PHASE4
NCT00320671 COMPLETED
Schizophrenia
Northwell Health
 2005-12 PHASE4
NCT02109562 COMPLETED
Schizophrenia
Indivior Inc.
 2014-04 PHASE3
NCT02918097 COMPLETED
Bipolar Disorder
Federal University of Rio Grande do Sul
 2010-05 PHASE4
NCT01624675 COMPLETED
Autistic Disorder in Children and Adolescents
Janssen Pharmaceutical K.K.
 2012-09 PHASE3
NCT02087579 COMPLETED
Psychotic Disorders; Schizophrenia; Bipolar Disorder; Depressive Disorder
Janssen Research & Development, LLC
 2014-02 PHASE1
NCT01411085 COMPLETED
Schizophrenia; Alcoholism; Dual Diagnosis
Dartmouth-Hitchcock Medical Center
 2011-12 PHASE2
NCT02019329 COMPLETED
Schizophrenia
Hoffmann-La Roche
 2014-01 PHASE1
NCT01896349 UNKNOWN
Treatment Resistant Depression
Hospital de Clinicas de Porto Alegre
 2013-04
NCT02192723 COMPLETED
Schizophrenia
Beijing HuiLongGuan Hospital
 2012-06
NCT01844700 TERMINATED
High Risk MC4R Genotype; Low Risk MC4R Genotype; One Week or Less Antipsychotic Lifetime Exposure
Northwell Health
 2013-07 PHASE4
NCT00806234 COMPLETED
Psychotic Disorders
Johns Hopkins University
 2009-01 PHASE4
NCT00799383 COMPLETED
Risperidone-induced Hyperprolactinemia
Chadi A. Calarge
 2008-11 PHASE3
NCT01788774 COMPLETED
Schizophrenia; Schizoaffective Disorder
Rovi Pharmaceuticals Laboratories
 2013-04 PHASE1
NCT02535156 COMPLETED
Schizotypal Personality Disorder
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
 2003-01 PHASE1; PHASE2
NCT02013232 UNKNOWN
Schizophrenia
Beijing HuiLongGuan Hospital
 2013-02
NCT01822730 COMPLETED
Methamphetamine Dependence
Wei Hao
 2013-02 PHASE4
NCT01742390 UNKNOWN
Sexual Dysfunction; Hyperprolactinemia
Si Tianmei
 2013-02 PHASE4
NCT01813643 TERMINATED
Methamphetamine Dependence
Wei Hao
 2012-07 PHASE4
NCT01157351 COMPLETED
Schizophrenia
Janssen Scientific Affairs, LLC
 2010-05 PHASE4
NCT00314327 TERMINATED
Schizophrenia; Schizoaffective Disorder; Schizophreniform Disorder; Psychotic Disorder Not Otherwise Specified
Northwell Health
 2006-04 PHASE4
NCT01774435 COMPLETED
Schizophrenia
Endo USA Inc., a Keenova Therapeutics Company
 2012-10 PHASE1
NCT01510015 UNKNOWN
Cannabis Dependence; Psychostimulant Dependence
Tel-Aviv Sourasky Medical Center
 2012-01
NCT01623713 COMPLETED
Schizophrenia; Iloperidone; Efficacy
Jiangsu Hansoh Pharmaceutical Co., Ltd.
 2012-06 PHASE2
NCT01499563 COMPLETED
Schizophrenia
Intra-Cellular Therapies, Inc.
 2011-12 PHASE2
NCT02021201 TERMINATED
Schizophrenia
Birte Glenthoj
 2008-07 PHASE4
NCT01524380 COMPLETED
Schizophrenia
Beijing HuiLongGuan Hospital
 2011-09
NCT01592201 TERMINATED
Schizophrenia
Janssen Korea, Ltd., Korea
 2012-07 PHASE4
NCT01592110 COMPLETED
Schizophrenia
Zogenix, Inc.
 2012-07 PHASE1
NCT01677377 COMPLETED
Schizophrenia
Indivior Inc.
 2012-08 PHASE2
NCT01363349 TERMINATED
Schizophrenia; Cognitive Effect on Schizophrenic Patients
BioLineRx, Ltd.
 2011-05 PHASE2; PHASE3
NCT01423487 WITHDRAWN
Weight Gain; Amenorrhea
Central South University
 2011-08
NCT01516424 COMPLETED
Schizophrenia
Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
 2012-02 PHASE3
NCT01708616 COMPLETED
Healthy Volunteer
Hoffmann-La Roche
 2012-11 PHASE1
NCT00333177 COMPLETED
Schizophrenia
University of California, Los Angeles
 2006-03 PHASE4
NCT01109147 COMPLETED
Schizophrenia, Undifferentiated Type
Qualissima
 2010-12 PHASE4
NCT01370291 UNKNOWN
Schizophrenia
Xijing Hospital
 2011-06 PHASE3
NCT00796302 COMPLETED
Attention Deficit Disorder With Hyperactivity
Michael Aman
 2008-08 PHASE4
NCT01450514 COMPLETED
Chronic Schizophrenia; Schizoaffective Disorder
PharmaNeuroBoost N.V.
 2012-03 PHASE2
NCT00330551 COMPLETED
Schizophrenia
University of California, Los Angeles
 2006-03 PHASE4
NCT00794625 UNKNOWN
Attention Deficit Disorder With Hyperactivity
Joseph Blader
 2008-11 PHASE4
NCT01129674 TERMINATED
Schizophrenia
Eli Lilly and Company
 2010-06 PHASE2; PHASE3
NCT01295372 COMPLETED
Schizophrenia
H. Lundbeck A/S
 2011-04 PHASE3
NCT01193166 WITHDRAWN
Schizophrenia
Ortho-McNeil Janssen Scientific Affairs, LLC
 2010-08 PHASE4
NCT01722201 COMPLETED
Fasting
IPCA Laboratories Ltd.
 2012-06 PHASE1
NCT00629252 TERMINATED
Schizophrenia
University of Zurich
 2008-02
NCT01618760 COMPLETED
Fed
IPCA Laboratories Ltd.
 2012-05 PHASE1
NCT00389493 COMPLETED
Obsessive-Compulsive Disorder
New York State Psychiatric Institute
 2006-10
NCT00539071 COMPLETED
Schizophrenia; Schizoaffective Disorder
Northwestern University
 2008-03 PHASE4
NCT01086748 COMPLETED
Schizophrenia
Eli Lilly and Company
 2010-03 PHASE2
NCT01607762 COMPLETED
Healthy
Janssen Research & Development, LLC
 2012-02 PHASE1
NCT01376076 COMPLETED
Schizophrenia
Forest Laboratories
 2011-06 PHASE1
NCT02768649 COMPLETED
Schizophrenia
Indivior Inc.
 2011-04 PHASE1
NCT01207414 COMPLETED
Schizophrenia
Novartis
 2010-08 PHASE4
NCT00975611 TERMINATED
Schizophrenia; Schizoaffective Disorder
David C. Henderson, MD
 2009-10 PHASE4
NCT01259973 UNKNOWN
Pharmacogenetics; Healthy
Hospital Clinic of Barcelona
 2011-02 PHASE1
NCT00480844 UNKNOWN
Schizophrenia
Sheba Medical Center
 2008-10 PHASE4
NCT01175135 COMPLETED
Schizophrenia
Pfizer
 2010-10 PHASE2
NCT01977300 COMPLETED
Bipolar I Disorder
University of British Columbia
 2003-01 PHASE3
NCT01050582 COMPLETED
Schizophrenia; Bipolar Disorder; Autistic Disorder; Conduct and Other Disruptive Behavior Disorders
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
 2009-10 PHASE4
NCT00221403 COMPLETED
Bipolar Disorder
Children's Hospital Medical Center, Cincinnati
 2004-09 PHASE3
NCT00417482 COMPLETED
Alzheimer Disease; Psychotic Disorders; Agitation; Aggression
New York State Psychiatric Institute
 2004-08 PHASE4
NCT01391403 COMPLETED
Schizophrenia
Beijing HuiLongGuan Hospital
 2008-09 PHASE3
NCT00205699 COMPLETED
Aggression; Attention Deficit-Hyperactivity; Oppositional Defiant Disorder; Pervasive Development Disorders; Bipolar Disorder
Washington University School of Medicine
 2006-04 PHASE4
NCT01057849 UNKNOWN
Schizophrenia
Peking University
 2008-09
NCT00509067 COMPLETED
Schizophrenia
Georgetown University
 2007-11 PHASE2
NCT00435370 COMPLETED
Smoking Cessation; Schizophrenia
Baylor College of Medicine
 2006-11 PHASE3
NCT00827840 COMPLETED
Schizophrenia
Chonnam National University Hospital
 2008-11 PHASE4
NCT00330863 COMPLETED
Schizophrenia; Schizoaffective Disorder
Northwell Health
 2006-05 PHASE4
NCT00594269 COMPLETED
Dementia
Sykehuset Innlandet HF
 2008-08 PHASE4
NCT00992407 COMPLETED
Schizophrenia
Janssen Korea, Ltd., Korea
 2007-12 PHASE4
NCT00573287 COMPLETED
Cannabis-Related Disorder; Substance-Related Disorders; Schizophrenia; Psychotic Disorders
Dartmouth-Hitchcock Medical Center
 2006-06
NCT00352339 UNKNOWN
Schizophrenia
Inje University
 2006-08 PHASE4
NCT01140620 COMPLETED
Healthy Volunteers; Schizophrenia
University of Manchester
 2010-06 PHASE4
NCT00245206 COMPLETED
Schizophrenia; Alzheimer's Disease; Dementia
Veterans Medical Research Foundation
 2005-08 PHASE4
NCT00272597 COMPLETED
Psychosis; Schizophrenia
University of British Columbia
 2005-09 PHASE4
NCT01083381 UNKNOWN
Schizophrenia
Farzan Institute
 2010-02 PHASE2
NCT00746252 TERMINATED
Bipolar Disorder
University of Maryland, Baltimore
 2008-06
NCT00206960 COMPLETED
Schizophrenia
Birte Glenthoj
 1998-01
NCT00385801 COMPLETED
Cocaine Dependence
Massachusetts General Hospital
 2005-09 PHASE2
NCT00723580 COMPLETED
Sleep Disorders, Circadian Rhythm; Insomnia; Psychomotor Agitation
Child Psychopharmacology Institute
 2008-05
NCT01284959 COMPLETED
Schizophrenia
Chonbuk National University Hospital
 2010-06 PHASE4
NCT00641745 COMPLETED
Schizophrenia; Schizoaffective Disorder
Sumitomo Pharma America, Inc.
 2008-03 PHASE3
NCT00937261 UNKNOWN
Schizophrenia
University of California, Irvine
 2009-07 PHASE4
NCT02456454 COMPLETED
Bipolar Disorder
Nationwide Children's Hospital
 2006-01 PHASE3
NCT00921804 COMPLETED
Schizophrenia
AstraZeneca
 2009-06 PHASE2
NCT00845026 COMPLETED
Schizophrenia
Denovo Biopharma LLC
 2009-03 PHASE2
NCT00817648 COMPLETED
Schizophrenia
Shanghai Mental Health Center
 2008-12 PHASE4
NCT00711269 COMPLETED
Schizophrenia
Sumitomo Pharma Co., Ltd.
 2008-06-27 PHASE3
NCT01119638 COMPLETED
Agitation; Psychosis; Alzheimer's Disease
Abarbanel Mental Health Center
 2008-04 PHASE4
NCT00946985 TERMINATED
Schizophrenia
Ortho-McNeil Janssen Scientific Affairs, LLC
 2009-06 PHASE4
NCT00857818 TERMINATED
Schizophrenia; Schizoaffective Disorder; Bipolar I Disorder; Metabolic Syndrome
Otsuka Pharmaceutical Development & Commercialization, Inc.
 2009-04 PHASE3
NCT00378092 COMPLETED
Schizophrenia
Janssen Cilag N.V./S.A.
 2006-04 PHASE4
NCT00640562 COMPLETED
Schizophrenia; Depression
AstraZeneca
 2008-02 PHASE3
NCT00099983 COMPLETED
Stress Disorders; Post-Traumatic
US Department of Veterans Affairs
 2006-10 PHASE2
NCT00761670 COMPLETED
Schizophrenia
Sanofi
 2008-09 PHASE4
NCT00932529 COMPLETED
Psychotic Disorders
University of Bergen
 2003-02 PHASE4
NCT00305474 UNKNOWN
Schizophrenia
Central South University
 2003-12 PHASE4
NCT00810667 COMPLETED
Schizophrenia; Cognition
H. Lundbeck A/S
 2008-11 PHASE2
NCT00825552 UNKNOWN
Severe Mood Dysregulation
Federal University of Rio Grande do Sul
 2009-01
NCT00140426 COMPLETED
Anorexia Nervosa
University of Colorado, Denver
 2004-08 PHASE4
NCT00934635 TERMINATED
Schizophrenia
Janssen-Cilag G.m.b.H
 2009-09 PHASE4
NCT01010776 COMPLETED
Schizophrenia
Janssen-Cilag Farmaceutica Ltda.
 2008-02 PHASE4
NCT00418873 TERMINATED
Schizophrenia
Astellas Pharma Inc
 2007-03 PHASE4
NCT00423878 COMPLETED
Schizophrenia; Schizoaffective Disorder
National Institute of Mental Health (NIMH)
 2007-01 PHASE4
NCT00600756 COMPLETED
Schizophrenic Disorders
AstraZeneca
 2008-01 PHASE3
NCT00132314 COMPLETED
Schizoaffective Disorder; Schizophrenia
US Department of Veterans Affairs
 2006-09 PHASE3
NCT00576732 COMPLETED
Autistic Disorder; Autism
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
 2007-12 PHASE4
NCT00439634 TERMINATED
Schizophrenia
Sanofi
 2007-02 PHASE2
NCT00694707 COMPLETED
Schizophrenia
Forest Laboratories
 2008-06-30 PHASE2
NCT00722176 COMPLETED
Schizophrenia
BioLineRx, Ltd.
 2008-06 PHASE2
NCT00768612 WITHDRAWN
Schizophrenia
Wyeth is now a wholly owned subsidiary of Pfizer
 2008-11 PHASE2
NCT00998608 TERMINATED
Schizophrenia
Kaohsiung Kai-Suan Psychiatric Hospital
 2007-08 PHASE4
NCT00567710 COMPLETED
Schizophrenia
BioLineRx, Ltd.
 2008-07 PHASE2
NCT00130923 COMPLETED
Schizophrenia; Psychotic Disorders; Substance Abuse; Alcohol Abuse
Dartmouth-Hitchcock Medical Center
 2005-09 PHASE4
NCT00821600 COMPLETED
Psychotic Disorders; Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
 2008-12 PHASE1
NCT00589914 COMPLETED
Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
 2007-03 PHASE3
NCT00584701 COMPLETED
Autism
University of California, San Francisco
 2008-01 PHASE2; PHASE3
NCT00256997 TERMINATED
Schizophrenia
Janssen-Ortho Inc., Canada
 2006-01 PHASE4
NCT00633802 UNKNOWN
Borderlone Personality Disorder
Tel-Aviv Sourasky Medical Center
 2004-04
NCT00391222 COMPLETED
Bipolar Disorder
Janssen Pharmaceutica N.V., Belgium
 2006-11 PHASE3
NCT00508157 TERMINATED
Metabolic Syndrome; Schizophrenia
Bristol-Myers Squibb
 2007-11 PHASE4
NCT00277654 COMPLETED
Bipolar Disorder; Anxiety Disorder
Lindner Center of HOPE
 2004-02 PHASE3
NCT00044655 COMPLETED
Schizophrenia
Icahn School of Medicine at Mount Sinai
 2001-07 PHASE4
NCT00859872 COMPLETED
Schizophrenia
Central South University
 2008-08 PHASE4
NCT00622011 TERMINATED
Delirium
Changhua Christian Hospital
 2008-01 PHASE4
NCT00698022 COMPLETED
Healthy
Corcept Therapeutics
 2008-11 PHASE1
NCT00571688 COMPLETED
Bipolar Disorder
Vanderbilt University
 2007-11 PHASE4
NCT01855074 COMPLETED
Schizophrenia; Schizophreniform Disorder; Schizoaffective Disorder
Janssen-Cilag Ltd.
 2007-11 PHASE4
NCT00526877 COMPLETED
Schizophrenia; Schizoaffective Disorders
Johnson & Johnson Taiwan Ltd
 2007-07-13 PHASE4
NCT00466310 COMPLETED
Schizophrenia
Duke University
 2007-02 PHASE1
NCT00604279 COMPLETED
Schizophrenia
Xian-Janssen Pharmaceutical Ltd.
 2008-01 PHASE3
NCT00515723 COMPLETED
Schizophrenia; Schizoaffective Disorder; Type 2 Diabetes Mellitus; Hyperglycemia
Washington University School of Medicine
 2001-09
NCT03730857 COMPLETED
Schizophrenia
Calo Psychiatric Center
 2008-01 PHASE1
NCT00246259 COMPLETED
Schizophrenia; Schizoaffective Disorder; Schizophreniform Disorder; Psychotic Disorders
Janssen-Ortho Inc., Canada
 2004-10 PHASE4
NCT00057681 COMPLETED
Bipolar Disorder
Washington University School of Medicine
 2003-02 PHASE3
NCT00712270 TERMINATED
Schizophrenia
Kettering Health Network
 2005-04 PHASE4
NCT01189006 COMPLETED
Schizophrenia
National Cheng-Kung University Hospital
 2005-01 PHASE2; PHASE3
NCT00493233 COMPLETED
Schizophrenia
Centre for Addiction and Mental Health
 2006-11
NCT00660595 TERMINATED
Schizophrenic Disorders
AstraZeneca
 2008-09 PHASE3
NCT00206102 COMPLETED
Schizophrenia; Schizoaffective Disorder
AstraZeneca
 2003-09 PHASE4
NCT00225498 COMPLETED
Schizophrenia
Northwell Health
 2002-06
NCT00498004 TERMINATED
Schizophrenia
Inje University
 2007-08 PHASE4
NCT00269919 COMPLETED
Schizophrenia; Schizoaffective Disorder
Janssen Korea, Ltd., Korea
 2005-08 PHASE4
NCT00535132 COMPLETED
Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
 2007-10 PHASE4
NCT00190749 COMPLETED
Schizophrenia; Schizoaffective Disorder
Eli Lilly and Company
 2003-10 PHASE4
NCT00563706 COMPLETED
Schizophrenia
Pfizer
 2007-12 PHASE2
NCT00177164 COMPLETED
Bipolar I Disorder
University of Pittsburgh
 2003-11 PHASE3
NCT01726335 COMPLETED
Schizophrenia
Janssen-Cilag Ltd.
 2006-01 PHASE4
NCT00366704 TERMINATED
Schizophrenia
Wyeth is now a wholly owned subsidiary of Pfizer
 2006-11 PHASE3
NCT00856583 COMPLETED
Schizophrenia
H. Lundbeck A/S
 2002-07 PHASE3
NCT00347425 COMPLETED
Schizophrenia and Schizoaffective Disorder
Solvay Pharmaceuticals
 2006-12 PHASE3
NCT00176202 COMPLETED
Bipolar Disorder
University of Illinois at Chicago
 2003-04 PHASE3
NCT00654576 COMPLETED
Schizophrenia
Central South University
 2005-02 PHASE4
NCT00337662 COMPLETED
Schizophrenia; Schizoaffective Disorder; Schizophreniform Disorder
Eli Lilly and Company
 2006-05 PHASE4
NCT00686140 COMPLETED
Schizophrenia
Beijing HuiLongGuan Hospital
 2006-06
NCT00216476 COMPLETED
Schizophrenia; Psychotic Disorders
Janssen-Cilag International NV
 2004-10 PHASE3
NCT00132678 COMPLETED
Bipolar Disorder
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
 2005-02 PHASE3
NCT00325689 COMPLETED
Schizophrenia; Schizoaffective Disorder
Otsuka Pharmaceutical Development & Commercialization, Inc.
 2006-07 PHASE4
NCT00204347 COMPLETED
Borderline Personality Disorder
University of Alabama at Birmingham
 2003-07 PHASE4
NCT00080145 COMPLETED
Child Development Disorders, Pervasive
Yale University
 2004-02
NCT00893256 COMPLETED
Schizophrenia; Negative Symptoms
National Institute of Mental Health and Neuro Sciences, India
 2004-12 PHASE4
NCT00284206 COMPLETED
Methamphetamine Dependence
Seattle Institute for Biomedical and Clinical Research
 2006-01 PHASE2
NCT00216632 COMPLETED
Schizophrenia; Psychotic Disorders
Janssen Pharmaceutica N.V., Belgium
 2005-03 PHASE4
NCT00179062 COMPLETED
Schizophrenia; Schizoaffective Disorder; Depressive Disorder, Major; Bipolar Disorder
Vanderbilt University
 2000-02
NCT00269035 COMPLETED
Schizophrenia
GlaxoSmithKline
 2005-06-21 PHASE1
NCT00053703 COMPLETED
Schizophrenia
University of North Carolina, Chapel Hill
 2002-02 PHASE4
NCT00352196 COMPLETED
Asperger's Disorder
Augusta University
 2001-11 PHASE4
NCT00000374 COMPLETED
Schizophrenia
Northwell Health
 1998-09 PHASE4
NCT00232687 COMPLETED
Schizophrenia
Otsuka Pharmaceutical Development & Commercialization, Inc.
 2005-06-01 PHASE4
NCT00167154 COMPLETED
Depression
University of Alabama at Birmingham
 2004-06 PHASE3
NCT01888107 COMPLETED
Schizophrenia; Schizoaffective Disorder
Janssen-Cilag S.p.A.
 2005-01 PHASE3
NCT00289861 COMPLETED
Schizophrenia
Massachusetts General Hospital
 2003-02 PHASE4
NCT00843687 COMPLETED
Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
 2005-09 PHASE3
NCT00314613 TERMINATED
Schizophrenia
Duke University
 2006-04 PHASE4
NCT00203788 COMPLETED
Schizophrenia
University of California, Los Angeles
 1999-05 PHASE4
NCT00205738 COMPLETED
Schizophrenia; Type 2 Diabetes Mellitus
Washington University School of Medicine
 2000-07
NCT01064271 COMPLETED
Healthy
Dr. Reddy's Laboratories Limited
 2006-10 PHASE1
NCT01064232 COMPLETED
Healthy
Dr. Reddy's Laboratories Limited
 2006-10 PHASE1
NCT00294255 COMPLETED
Bipolar Disorder
The University of Texas Health Science Center at San Antonio
 2003-03 PHASE4
NCT00133822 COMPLETED
Post-Traumatic Stress Disorders
Emory University
 2004-04 PHASE1; PHASE2
NCT00048802 COMPLETED
Bipolar Disorder
Northwell Health
 2002-08 PHASE4
NCT00304616 COMPLETED
Schizophrenia
Korea Otsuka Pharmaceutical Co., Ltd.
 2004-10 PHASE4
NCT00215579 COMPLETED
Schizophrenia; Schizoaffective Disorder
Duke University
 2004-04 PHASE4
NCT00148083 COMPLETED
Schizophrenia; Schizoaffective Disorder
University of Illinois at Chicago
 2005-09 PHASE3
NCT00178854 WITHDRAWN
Treatment Resistant Depression
Vanderbilt University Medical Center
 2004-05 PHASE4
NCT00103727 COMPLETED
Schizophrenia
GlaxoSmithKline
 2004-12 PHASE2
NCT00300963 COMPLETED
Schizophrenia
GlaxoSmithKline
 2004-12 PHASE2
NCT00237913 COMPLETED
Schizophrenia
Otsuka Pharmaceutical Development & Commercialization, Inc.
 2004-07 PHASE3
NCT00206765 TERMINATED
Major Depressive Disorder With Panic Attacks; Panic Disorder
Beth Israel Medical Center
 2003-01 PHASE2
NCT00364429 TERMINATED
Schizophrenia
GlaxoSmithKline
 2005-07 PHASE1
NCT01234454 COMPLETED
Schizophrenia
University of North Carolina, Chapel Hill
 2002-01
NCT00073658 COMPLETED
Dementia
University of Pittsburgh
 2000-01 PHASE2
NCT00183625 COMPLETED
Schizophrenia
University of California, Los Angeles
 2000-06 PHASE4
NCT00159081 COMPLETED
Schizophrenia
Heinrich-Heine University, Duesseldorf
 2000-11 PHASE4
NCT00235352 COMPLETED
Schizophrenia
North Suffolk Mental Health Association
 2002-02 PHASE2; PHASE3
NCT00034892 COMPLETED
Schizophrenia; Psychotic Disorders; Mental Health; Mental Disorders
AstraZeneca
 2002-03 PHASE3
NCT00848432 COMPLETED
Schizophrenia
Capital Medical University
 2002-12 PHASE4
NCT00161018 COMPLETED
Schizophrenia
University of Maryland, Baltimore
 2003-11 PHASE3
NCT01222975 COMPLETED
Healthy
Ranbaxy Laboratories Limited
 2004-10
NCT01222923 COMPLETED
Healthy
Ranbaxy Laboratories Limited
 2004-10
NCT01155934 COMPLETED
Healthy
Dr. Reddy's Laboratories Limited
 2004-08 PHASE1
NCT00255879 COMPLETED
Dyskinesia, Drug-Induced
University of California, San Diego
 1999-01 PHASE1
NCT01155921 COMPLETED
Healthy
Dr. Reddy's Laboratories Limited
 2004-08 PHASE1
NCT00790075 COMPLETED
Agitation
Stony Brook University
 2003-01 PHASE4
NCT01282632 COMPLETED
Subjects Had Unipolar, Non-psychotic Major Depression
Sunnybrook Health Sciences Centre
 2002-08 PHASE1; PHASE2
NCT00182013 COMPLETED
Bipolar Spectrum Disorder
Massachusetts General Hospital
 2001-06 PHASE4
NCT00621998 COMPLETED
Neuroleptic-Induced Tardive Dyskinesia
Taoyuan Psychiatric Center, Ministry of Health and Welfare, Executive Yuan, R.O.C. Taiwan
 2000-07 PHASE4
NCT00457106 COMPLETED
Major Depression With Panic Attacks; Panic Disorder
Beth Israel Medical Center
 2002-06
NCT00049946 COMPLETED
Schizophrenia
GlaxoSmithKline
 2002-10 PHASE2
NCT00237861 COMPLETED
Schizophrenia
Yale University
 PHASE4
NCT00034905 COMPLETED
Schizophrenia
AstraZeneca
 2001-07 PHASE4
NCT00158028 COMPLETED
Schizotypal Personality Disorder
Icahn School of Medicine at Mount Sinai
 1995-11
NCT00829894 COMPLETED
Healthy
Teva Pharmaceuticals USA
 2001-06 PHASE1
NCT00830349 COMPLETED
Healthy
Teva Pharmaceuticals USA
 2001-06 PHASE1
NCT00000309 TERMINATED
Cocaine-Related Disorders
Butler Hospital
 1994-08 PHASE2
NCT00000317 COMPLETED
Cocaine-Related Disorders; Substance-Related Disorders
New York State Psychiatric Institute
 1996-08 PHASE2
NCT00000347 COMPLETED
Cocaine-Related Disorders
National Institute on Drug Abuse (NIDA)
 1997-07 PHASE2
NCT00000342 COMPLETED
Cocaine-Related Disorders
National Institute on Drug Abuse (NIDA)
 1996-07 PHASE2
NCT00000310 TERMINATED
Cocaine-Related Disorders
National Institute on Drug Abuse (NIDA)
 1996-01 PHASE2
NCT00236587 COMPLETED
Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
 2001-11 PHASE3
NCT00257075 COMPLETED
Bipolar Disorders; Manic Episode
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
 2000-12 PHASE3
NCT00210691 COMPLETED
Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
 1999-12 PHASE3
NCT00216580 COMPLETED
Schizophrenia
Janssen Pharmaceutica N.V., Belgium
 2004-02 PHASE3
NCT00088075 COMPLETED
Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
 2004-08 PHASE3
NCT00563017 UNKNOWN
Schizophrenia, Catatonic; Schizophrenia, Disorganized; Schizophrenia, Paranoid; Schizophrenia; Psychotic Disorders
Hospital Authority, Hong Kong
 2004-10
NCT00249236 COMPLETED
Bipolar Disorder; Manic Episode
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
 2001-03 PHASE3
NCT00231335 COMPLETED
Schizophrenia; Schizoaffective Disorder
Emory University
 2006-03 PHASE4
NCT00216528 COMPLETED
Schizophrenia
Janssen Korea, Ltd., Korea
 2005-07 PHASE4
NCT00315081 UNKNOWN
Schizophrenia; Hyperprolactinemia
University Hospital, Bonn
 2006-05 PHASE3
NCT00034775 COMPLETED
Schizophrenia; Psychotic Disorders
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
 2001-08 PHASE3
NCT00369239 COMPLETED
Schizophrenia; Psychotic Disorders; Schizoaffective Disorder
Janssen Pharmaceutica N.V., Belgium
 2006-03 PHASE4
NCT00297739 COMPLETED
Aggression
Armenteros, Jorge L., M.D., P.A.
 2003-01 PHASE4
NCT00236548 COMPLETED
Schizophrenia; Psychotic Disorders
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
 PHASE3
NCT00208182 COMPLETED
Post-Traumatic Stress Disorder
Creighton University
 2001-07 PHASE4
NCT00828958 COMPLETED
Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
 2006-02 PHASE3
NCT00179244 COMPLETED
Unipolar Depression
Vanderbilt University
 2004-07 PHASE3
NCT00076115 COMPLETED
Bipolar Disorder
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
 2003-12 PHASE3
NCT00174577 UNKNOWN
Major Depression
Rhode Island Hospital
 2003-02 PHASE3
NCT00250367 COMPLETED
Bipolar Disorder; Manic Disorder
Janssen Pharmaceutica N.V., Belgium
 1997-10 PHASE3
NCT00005014 COMPLETED
Autistic Disorder
National Institute of Mental Health (NIMH)
 1997-10 PHASE3
NCT00006195 UNKNOWN
Schizophrenia
National Center for Research Resources (NCRR)
NCT00216554 COMPLETED
Bipolar Disorder
Janssen Korea, Ltd., Korea
 2004-09 PHASE4
NCT00012558 COMPLETED
Bipolar Disorder
National Institute of Mental Health (NIMH)
 1998-09
NCT00015548 COMPLETED
Alzheimer's Disease
National Institute of Mental Health (NIMH)
 2001-03
NCT00272584 COMPLETED
Psychosis, Schizophrenia
University of British Columbia
 2001-06 PHASE4
NCT00236470 COMPLETED
Disruptive Behavior Disorder
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
 2002-01 PHASE3
NCT00254930 COMPLETED
Learning Disorders; Child Behavior Disorders
Janssen-Cilag Ltd.
 2003-09 PHASE3
NCT00249145 COMPLETED
Dementia; Alzheimer Disease; Dementia, Vascular
Janssen Pharmaceutica N.V., Belgium
 1995-04 PHASE3
NCT00639483 COMPLETED
Schizophrenia
Pfizer
 2003-03 PHASE2
NCT00018668 COMPLETED
Schizophrenia
US Department of Veterans Affairs
 2000-10 PHASE4
NCT00166595 COMPLETED
Child Development Disorders, Pervasive
Children's Hospital Medical Center, Cincinnati
 2003-02 PHASE1; PHASE2
NCT00261508 COMPLETED
DCild Development Disorders, Pervasive; Autistic Disorder; Developmental Disabilities; Asperger Syndrome; Rett Syndrome
Janssen-Ortho Inc., Canada
 1999-08 PHASE3
NCT00034749 COMPLETED
Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
 2001-04 PHASE3
NCT00399698 COMPLETED
Oppositional Defiant Disorder; Conduct Disorder; Attention Deficit/Hyperactivity Disorder (ADHD); Intermittent Explosive Disorder; Impulse-Control Disorders; Adjustment Disorder; Bipolar Disorder; Pervasive Developmental Disorder
Ohio State University
 1999-05 PHASE3
NCT00086112 COMPLETED
Anxiety Disorders
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
 PHASE3
NCT00140166 COMPLETED
Acute Schizophrenia
Beersheva Mental Health Center
 2005-07 PHASE4
NCT00065273 COMPLETED
Mental Retardation; Developmental Delay Disorder
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
 1998-07 PHASE3
NCT00034580 COMPLETED
Bipolar Disorder
Eli Lilly and Company
 2001-08 PHASE4
NCT00287820 COMPLETED
Schizophrenia; Diabetes; Metabolic Syndrome; Hyperglycemia
Nathan Kline Institute for Psychiatric Research
 2004-02 PHASE4
NCT00939926 COMPLETED
Healthy
Torrent Pharmaceuticals Limited
 PHASE1
NCT00147394 COMPLETED
Child Development Disorders, Pervasive
Children's Hospital Medical Center, Cincinnati
 2001-12 PHASE1
NCT00361166 COMPLETED
Schizophrenia
ACADIA Pharmaceuticals Inc.
 2005-08 PHASE2
NCT00266552 COMPLETED
Conduct Disorder; Disruptive Behavior Disorder; Oppositional Defiant Disorder
Janssen Pharmaceutica N.V., Belgium
 PHASE3
NCT00254241 COMPLETED
Schizophrenia
AstraZeneca
 2002-05 PHASE4
NCT00174200 COMPLETED
Schizophrenia; Psychotic Disorders
Pfizer
 2004-12
NCT00034762 COMPLETED
Dementia; Alzheimer Disease; Mental Disorders
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
 2000-12 PHASE3
NCT00246272 COMPLETED
Schizophrenia
Janssen-Ortho Inc., Canada
 2004-10 PHASE3
NCT00159770 COMPLETED
Schizophrenia; Schizoaffective Disorder; Psychotic Disorders
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
 2001-11 PHASE3
NCT00249171 COMPLETED
Schizophrenia; Psychotic Disorders; Emergency Treatment
Janssen Pharmaceutica N.V., Belgium
 2001-06 PHASE4
NCT00044681 COMPLETED
Depressive Disorder; Depressive Disorder, Major; Depression
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
 2002-10 PHASE3
NCT00283179 COMPLETED
Schizophrenia; Schizoaffective Disorder
Taiwan Otsuka Pharm. Co., Ltd
 2004-03 PHASE3
NCT00000339 UNKNOWN
Cocaine-Related Disorders
National Institute on Drug Abuse (NIDA)
 1996-06 PHASE1
NCT00485498 COMPLETED
Schizophrenia
Eli Lilly and Company
 2003-04 PHASE4
NCT00000267 COMPLETED
Cocaine-Related Disorders
National Institute on Drug Abuse (NIDA)
 PHASE2
NCT00791232 COMPLETED
Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
 2003-03 PHASE1
NCT00305422 COMPLETED
Schizophrenia
AstraZeneca
 2001-11 PHASE3
NCT00061802 COMPLETED
Schizophrenia; Schizoaffective Disorder
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
 2003-06 PHASE4
NCT00157378 UNKNOWN
Schizophrenia, First-Episode
Ludwig-Maximilians - University of Munich
 2000-11 PHASE4
NCT00224315 COMPLETED
Schizophrenia, Schizoaffective Disorder
Central Institute of Mental Health, Mannheim
 2003-11 PHASE4
NCT00240708 COMPLETED
Schizophrenia
Janssen Pharmaceutical K.K.
 2004-06 PHASE3
NCT00253136 COMPLETED
Schizophrenia; Psychotic Disorders
Janssen, LP
 1999-11 PHASE3
NCT01320410 COMPLETED
Healthy
Rovi Pharmaceuticals Laboratories
 PHASE1
NCT00645372 COMPLETED
Schizophrenia
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
 2004-07 PHASE3
NCT00534183 COMPLETED
Metabolic Syndrome; Diabetes; Obesity
Central Institute of Psychiatry, Ranchi, India
 2006-06
NCT00208143 COMPLETED
Schizophrenia; Schizoaffective Disorder; Substance Abuse; Substance Dependence
Creighton University
 2003-11 PHASE4
NCT00253162 COMPLETED
Bipolar Disorders; Manic Disorder
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
 2001-03 PHASE3
NCT00014001 COMPLETED
Schizophrenia
National Institute of Mental Health (NIMH)
 2000-12 PHASE4
NCT00331825 COMPLETED
Schizophrenia; Extrapyramidal Syndrome
Taoyuan Psychiatric Center, Ministry of Health and Welfare, Executive Yuan, R.O.C. Taiwan
 2000-07 PHASE4
NCT00261430 COMPLETED
Schizophrenia
Janssen, LP
 PHASE4
NCT00236444 COMPLETED
Attention Deficit and Disruptive Behavior Disorders
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
 2001-12 PHASE3
NCT00253123 COMPLETED
Dementia; Alzheimer Disease; Dementia, Vascular
Janssen, LP
 PHASE3
NCT00246285 COMPLETED
Schizophrenia; Psychotic Disorders
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
 2001-04 PHASE3
NCT00378183 COMPLETED
Schizoaffective Disorder; Schizophrenia
Janssen, LP
 2001-02 PHASE4
NCT00203775 TERMINATED
Psychosis; Aggression
University of Connecticut
 2002-07
NCT00645502 COMPLETED
Schizophrenia; Schizoaffective Disorders
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
 2003-06 PHASE1
NCT00203723 TERMINATED
Major Depression
University of California, Los Angeles
 2005-03 PHASE4
NCT00653406 COMPLETED
Schizophrenia
Janssen Pharmaceutical K.K.
 2002-11 PHASE1; PHASE2
NCT00433121 COMPLETED
Dementia
Sykehuset Innlandet HF
 2006-09 PHASE4
NCT00308360 COMPLETED
Schizophrenia
Nathan Kline Institute for Psychiatric Research
 1999-09 PHASE4
NCT00249119 COMPLETED
Schizophrenia; Psychotic Disorder
Janssen, LP
 PHASE3
NCT00558298 COMPLETED
Schizophrenia; Schizoaffective Disorder
Janssen, LP
 2000-02 PHASE3
NCT00236379 COMPLETED
Schizophrenia; Diabetes Mellitus
Janssen, LP
 PHASE4
NCT00297388 COMPLETED
Schizophrenia; Schizoaffective Disorder
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
 PHASE3
NCT00249158 COMPLETED
Dementia; Alzheimer Disease; Vascular Dementia
Janssen-Cilag Pty Ltd
 1998-03 PHASE3
NCT00215241 COMPLETED
Post-Traumatic Stress Disorder
Duke University
 2004-04 PHASE2; PHASE3
NCT00097032 COMPLETED
Bipolar Disorder
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
 2004-10 PHASE3
NCT00018291 COMPLETED
Alzheimer's Disease; Dementia
US Department of Veterans Affairs
 2001-01
NCT00174590 TERMINATED
Major Depression With Psychotic Features
Rush University Medical Center
 2001-09 PHASE3
NCT00108368 COMPLETED
Schizophrenia; Psychotic Disorders
US Department of Veterans Affairs
 2003-10 PHASE4
NCT00177567 COMPLETED
Bipolar Disorder
University of Pittsburgh
 2001-07 PHASE4
NCT00202007 COMPLETED
Schizophrenia
Otsuka Beijing Research Institute
 2005-02 PHASE2
NCT00220714 UNKNOWN
Schizophrenia
State University of New York - Downstate Medical Center
 2004-11 PHASE4
NCT00287742 TERMINATED
Alzheimer's Disease; Dementia
Janssen Pharmaceutical K.K.
 2002-03 PHASE3
NCT00249132 COMPLETED
Schizophrenia; Psychotic Disorders
Janssen, LP
 PHASE3
NCT00236457 COMPLETED
Schizophrenia; Psychotic Disorders
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
 2000-11 PHASE3
NCT00645515 TERMINATED
Schizophrenia
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
 2003-06 PHASE3
NCT00208819 COMPLETED
Senile Dementia, Alzheimer Type; Dementia, Alzheimer Type; Alzheimer Disease; Dementia
Emory University
 2003-09 PHASE4
NCT00939497 COMPLETED
Healthy
Torrent Pharmaceuticals Limited
 PHASE1
NCT00253110 COMPLETED
Schizophrenia; Schizoaffective Disorder
Janssen, LP
 1996-05 PHASE4
NCT00169988 COMPLETED
Prodromal Schizophrenia; Psychotic Disorders
Northwell Health
 2004-03
NCT00796185 COMPLETED
Schizophrenia; Schizoaffective Disorder
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
 2003-08 PHASE1
NCT00250354 COMPLETED
Conduct Disorder; Oppositional Defiant Disorder; Disruptive Behavior Disorder
Janssen Pharmaceutica N.V., Belgium
 1997-09 PHASE3
NCT00167479 COMPLETED
Bipolar Disorder; Panic Disorder; Generalized Anxiety Disorder
University of South Florida
 2003-09 PHASE4
NCT00073164 COMPLETED
Schizophrenia
Abbott
 2003-07 PHASE2
NCT00181935 COMPLETED
Bipolar Disorder; Mania
Massachusetts General Hospital
 2001-03 PHASE4
NCT00253149 COMPLETED
Bipolar Disorders; Manic Disorder
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
 PHASE3
NCT00203528 COMPLETED
Substance Abuse; Bipolar Depression
Tuscaloosa Research & Education Advancement Corporation
 2004-01 PHASE4
NCT00236353 COMPLETED
Schizophrenia; Psychotic Disorders
Janssen, LP
 2002-05 PHASE3
NCT00222495 COMPLETED
Psychotic Disorders; Schizophrenia; Schizophreniform Disorders; Schizoaffective Disorders
University of Minnesota
 2002-08
NCT00986336 COMPLETED
Bipolar Disorder
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
 2001-02 PHASE1
NCT00374764 COMPLETED
Autistic Disorder
Washington University School of Medicine
 2000-07
NCT00095134 COMPLETED
Major Depressive Disorder
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
 2004-10 PHASE3
NCT00495118 COMPLETED
Schizophrenia; Schizoaffective Disorder
Janssen, LP
 2001-10 PHASE3
NCT00249223 COMPLETED
Schizophrenia; Psychotic Disorders
Janssen Pharmaceutica N.V., Belgium
 2000-01 PHASE3
NCT00227123 COMPLETED
Bipolar Disorder; Cocaine Dependence; Methamphetamine Dependence
University of Texas Southwestern Medical Center
 2002-10
NCT00246246 COMPLETED
Bipolar Disorder
Janssen-Ortho Inc., Canada
 2004-01 PHASE3
NCT00004393 COMPLETED
Tourette Syndrome
National Center for Research Resources (NCRR)
 1997-07 PHASE2

(data from https://clinicaltrials.gov, updated on 2026-05-26)

Check the Risperidone product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Risperidone acts as a potent antagonist primarily targeting dopamine D2 and serotonin 5-HT2A receptors, which inhibits downstream monoaminergic signal transduction and dampens hyperactive dopaminergic neurotransmission in central nervous system pathways. This receptor blockade restores balanced neurotransmitter activity, providing therapeutic efficacy in mitigating symptoms of schizophrenia, schizoaffective disorder, and manic episodes of bipolar disorder evaluated across clinical studies.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.